News
globenewswire.comSCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwideglobenewswire.comJun 18
globenewswire.comSCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Teamglobenewswire.comJun 9
accessnewswire.comSCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYCaccessnewswire.comJun 4
globenewswire.comSCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041globenewswire.comJun 2
globenewswire.comSCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansionglobenewswire.comMay 18